NCT03289533View on ClinicalTrials.gov

A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 8, 2017

Primary Completion Date

August 27, 2019

Study Completion Date

October 25, 2019

Conditions
Carcinoma, Hepatocellular
Interventions
DRUG

Avelumab (MSB0010718C)

Patients will receive avelumab 10 mg/kg Q2W in combination with axitinib 5 mg BID.

DRUG

Axitinib (AG-013736)

Patients will receive avelumab 10 mg/kg Q2W in combination with axitinib 5 mg BID.

Trial Locations (7)

464-8681

Aichi Cancer Center Hospital, Nagoya

820-8505

Iizuka Hospital, Iizuka

589-8511

Kindai University Hospital, Department of Gastroenterology and Hepatology, Ōsaka-sayama

104-0045

National Cancer Center Hospital, Chuo-ku

181-8611

Kyorin University Hospital, Department of Medical Oncology, Mitaka-shi

180-8610

Japanese Red Cross Musashino Hospital, Musashino

810-8563

National Hospital Organization Kyushu Medical Center, Fukuoka

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03289533 - A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100) | Biotech Hunter | Biotech Hunter